Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1961 1
1968 1
1976 1
1980 1
1983 1
1984 1
1985 1
1988 1
1989 1
1990 1
1991 3
1992 3
1993 2
1994 1
1996 2
1997 1
1998 2
2000 3
2001 2
2002 4
2003 16
2004 17
2005 19
2006 30
2007 18
2008 25
2009 28
2010 18
2011 19
2012 25
2013 31
2014 34
2015 54
2016 51
2017 52
2018 57
2019 60
2020 53
2021 52
2022 49
2023 47
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

694 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for B. paola
Your search for B. Pakla retrieved no results
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
CONCLUSIONS: In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including …
CONCLUSIONS: In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenan …
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I. Pujade-Lauraine E, et al. JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258. JCO Precis Oncol. 2023. PMID: 36716415 Free PMC article. Clinical Trial.
PURPOSE: The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant progression-free survival (PFS) benefit over placebo plus bevacizumab, particularly in patients with homologous …
PURPOSE: The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer …
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
BACKGROUND: In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted in prolonged progression-free survival (PFS), particularly for homologous recombination deficiency-pos …
BACKGROUND: In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high …
Editorial overview: Developmental neuroscience 2017.
Arlotta P, Vanderhaeghen P. Arlotta P, et al. Curr Opin Neurobiol. 2017 Feb;42:A1-A4. doi: 10.1016/j.conb.2017.01.003. Epub 2017 Jan 20. Curr Opin Neurobiol. 2017. PMID: 28117212 No abstract available.
Potential of GABA(B) Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder.
Maccioni P, Colombo G. Maccioni P, et al. CNS Drugs. 2019 Feb;33(2):107-123. doi: 10.1007/s40263-018-0596-3. CNS Drugs. 2019. PMID: 30604283 Review.
The orthosteric gamma-aminobutyric acid(B) (GABA(B)) receptor agonist baclofen is currently considered a therapeutic option for alcohol use disorder (AUD); however, the safety profile of baclofen is a concern, thus arousing interest in the positive allosteric modula …
The orthosteric gamma-aminobutyric acid(B) (GABA(B)) receptor agonist baclofen is currently considered a therapeutic option fo …
Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridines with potent photo-antiproliferative activity.
Spanò V, Giallombardo D, Cilibrasi V, Parrino B, Carbone A, Montalbano A, Frasson I, Salvador A, Richter SN, Doria F, Freccero M, Cascioferro S, Diana P, Cirrincione G, Barraja P. Spanò V, et al. Eur J Med Chem. 2017 Mar 10;128:300-318. doi: 10.1016/j.ejmech.2017.02.008. Epub 2017 Feb 7. Eur J Med Chem. 2017. PMID: 28213283
Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridines were synthesized as a new class of tricyclic system in which the pyridine ring is annelated to a cycloheptapyrrole scaffold, with the aim of obtaining new photosensitizing agents with improved antiproliferative activity and lowe …
Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridines were synthesized as a new class of tricyclic system in which the pyridine ring is annela …
Genetic diversity and its impact on disease severity in respiratory syncytial virus subtype-A and -B bronchiolitis before and after pandemic restrictions in Rome.
Pierangeli A, Nenna R, Fracella M, Scagnolari C, Oliveto G, Sorrentino L, Frasca F, Conti MG, Petrarca L, Papoff P, Turriziani O, Antonelli G, Stefanelli P, Palamara AT, Midulla F. Pierangeli A, et al. J Infect. 2023 Oct;87(4):305-314. doi: 10.1016/j.jinf.2023.07.008. Epub 2023 Jul 24. J Infect. 2023. PMID: 37495189 Free article.
Subtype-specific data were compared among seasons. RESULTS: Predominance of RSV-A and -B alternated in the pre-pandemic seasons; RSV-A dominated in 2021-2022 whereas RSV-B was predominant in 2022-2023. ...CONCLUSIONS: The intense RSV peak in 2021-2022, driven by RSV …
Subtype-specific data were compared among seasons. RESULTS: Predominance of RSV-A and -B alternated in the pre-pandemic seasons; RSV- …
Pathogenicity, population genetics and dissemination of Bacillus anthracis.
Pilo P, Frey J. Pilo P, et al. Infect Genet Evol. 2018 Oct;64:115-125. doi: 10.1016/j.meegid.2018.06.024. Epub 2018 Jun 20. Infect Genet Evol. 2018. PMID: 29935338 Free article. Review.
Sequencing technologies are also used for forensic applications to trace unintended or criminal acts of release of B. anthracis. Under natural conditions, B. anthracis generally affects domesticated and wild ruminants in arid ecosystems. The more recently discovered …
Sequencing technologies are also used for forensic applications to trace unintended or criminal acts of release of B. anthracis. Unde …
694 results